Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03346837 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT03346837 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 53 participants.
The verdict
NCT03346837, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG BMS-986205
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2017-11-22 |
| Est. Completion | 2017-12-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03346837
The ClinicalTrials.gov registry entry for NCT03346837 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT03346837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03346837 about?
NCT03346837 is a clinical study titled "A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects". Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.
What is the current status of trial NCT03346837?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2017-11-22. Estimated completion is 2017-12-20.
What interventions are being tested in trial NCT03346837?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), BMS-986205 (DRUG).
Who is sponsoring clinical trial NCT03346837?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.